Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
114 participants
OBSERVATIONAL
2015-01-31
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Another issue is that the diagnostic difficulties in patients with LVddf and HFpEF stem from the limited possibility to assess the hemodynamic response to exercise. Thus, there is a need for more detailed methods of cardiovascular monitoring while exercise testing.
We hypothesize that some new noninvasive hemodynamic parameters, characterizing left ventricular (LV) function and arterial stiffness, may help to predict the risk of cardiovascular events and future occurrence of LVddf/HFpEF. Moreover, we assume that cardiopulmonary exercise test (CPET), completed with new methods of noninvasive hemodynamic monitoring (impedance cardiography and applanation tonometry), would provide additional value in the assessment of the cardiovascular hemodynamic response to exercise.
The study is intended to verify these hypothesis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Aerobic Exercise Training on Sympathetic Vasoconstriction and Vascular Function in Essential Hypertension
NCT03778489
The Effects of Dietary Salt on Post-exercise Hypotension
NCT03565653
Association Between Left Ventricular Deformation and Aerobic Exercise Capacity in Untreated Arterial Hypertension
NCT02346695
Hemodynamic and Salivary Responses of 12 Weeks of Training With Different Anti-hypertensive
NCT03529838
National Survey on Hypertension in Cardiologic Private Practice
NCT00695175
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
AH is associated with cardiovascular hemodynamic alterations, including left ventricular diastolic dysfunction (LVddf). In consequence of increased blood pressure, the effectiveness of LV as a blood pump decreases and the symptoms of heart failure (HF), even with preserved ejection fraction (HFpEF), may occur. At the early stage, patients' complaints are not specific and difficult to clinical interpretation. As a consequence, these subjects frequently remain undiagnosed. Thus, the identification of noninvasive markers related with the progression from the asymptomatic AH to LVddf/HFpEF would be beneficial.
Another issue is that the diagnostic difficulties in patients with LVddf and HFpEF stem from the limited possibility to assess the hemodynamic response to exercise. Thus, there is a need for more detailed methods of cardiovascular monitoring while exercise testing.
The investigators hypothesize that some new noninvasive hemodynamic parameters, characterizing left ventricular (LV) function and arterial stiffness, may help to predict the risk of cardiovascular events and future occurrence of LVddf/HFpEF. Moreover, the investigators assume that cardiopulmonary exercise test (CPET), completed with new methods of noninvasive hemodynamic monitoring (impedance cardiography and applanation tonometry), would provide additional value in the assessment of the cardiovascular hemodynamic response to exercise.
Aims:
1. The identification of the new markers of cardiovascular risk in patients with arterial hypertension..
2. The identification of the new markers of progression from normal left ventricular diastolic function to left ventricular diastolic dysfunction.
3. The identification of the new noninvasive markers of progression to symptomatic heart failure.
4. The evaluation of the feasibility and usefulness of new methods of noninvasive hemodynamic monitoring (impedance cardiography and applanation tonometry) in the assessment of the cardiovascular hemodynamic response to exercise.
5. Multivariate assessment of cardiovascular response to the controlled exercise, taking into account left ventricular diastolic function and symptoms of heart failure.
6. The relation between laboratory markers of left ventricular remodeling with resting and exercise (noninvasive) hemodynamics.
The study will be performed in a prospective and observational design. No less than 120 hypertensive subjects will be enrolled.
After recruitment the following assessment will be performed:
* anamnesis and physical examination with anthropometrics (including body composition analysis with use of bioimpedance method);
* electrocardiogram;
* echocardiography (resting), including assessment of left ventricular systolic (2-D left ventricular ejection fraction, longitudinal strain) and diastolic function (including tissue Doppler imaging);
* impedance cardiography (resting);
* Applanation tonometry (resting);
* 24-h Holter-ekg (including heart rate variability analysis);
* 24-h ambulatory blood pressure monitoring;
* flow-mediated dilation of brachial artery (FMD);
* 6-minute walking test (6-MWT);
* Cardiopulmonary exercise test (CPET), supported by hemodynamic monitoring with impedance cardiography and applanation tonometry;
* Quality of life assessment (SF 36 questionnaire);
* Laboratory tests (including creatinine, urea, uric acid, lipids, glucose, microalbuminuria, N-terminal of the prohormone brain natriuretic peptide, galectin-3, copeptin, soluble ST2, Growth differentiation factor 15 (GDF-15), human tissue inhibitor of metalloproteinases 1 (TIMP-1), metalloproteinase 2 (MMP-2), metalloproteinase 9 (MMP-9), syndecan-1).
After 12 months (first control visit) and 24 months (second control visit) the echocardiography and clinical assessment (HF symptoms) will be performed to identify: 1/ patients with new onset LVDdf (among group N); 2/ patients with new onset HF (among group D)
Morover, the follow-up of min 48 months concerning cardiovascular events will be performed (as defined below)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group N
The subjects with no symptoms of HF and normal left ventricular diastolic function (no less than 40 subjects)
No interventions assigned to this group
Group D
The subjects with no symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
No interventions assigned to this group
Group D_HF
The subjects with symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 40-75 years
* arterial hypertension diagnosed ≥3 months before recruitment.
Exclusion Criteria
* coronary artery disease
* systolic heart failure (LVEF below 45%) and/or severe heart defect (i.e. valvular disease)
* severe pulmonary diseases (COPD stage C/D, uncontrolled asthma, pulmonary hypertension, pulmonary embolism)
* chronic kidney disease (MDRD eGFR\<60 ml/min/1.73m2)
* severe inflammatory disease
* severe mental and physical disorders
* polyneuropathy
* obesity with BMI \> 40 kg/m2
* life expectancy less than 12 months in the opinion of the physician
* patients' refusal to participate.
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Military Institute od Medicine National Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Paweł Krzesiński
Lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Military Institute of Medicine
Warsaw, Masovian Voivodeship, Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0000000336
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.